A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

A recent study shows that First-line serplulimab plus chemotherapy improves PFS and OS and promises another treatment option for these patients. Their results demonstrate that adding serplulimab to chemotherapy significantly improves survival in advanced squamous NSCLC patients, with manageable safety.


Posted on:

Subscribe to our Newsletter

Full Name



Your form submitted successfully!


Sorry! your form was not submitted properly, Please check the errors above.